5 Best Fast Growth Stocks to Invest In Now

3. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

On April 19, 2026, Barclays analyst Etzer Darout raised the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $225 from $224 and maintained an Overweight rating on the shares as part of a Q1 preview across the small and mid-cap biotechnology group.

Earlier in April, Raymond James resumed coverage of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) with an Outperform rating and a $227 price target, saying the story has moved beyond the “it looks inexpensive/fairly valued, but where can I get upside?” view, citing improved visibility into the tail value of the Epidiolex franchise and “highly competitive” data from zanidatamab in gastroesophageal adenocarcinoma.

Last month, Piper Sandler raised its price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $232 from $219 and maintained an Overweight rating, noting the company trades at about seven times EV/2026E EBITDA while offering visibility into double-digit top-line growth starting in 2027. The firm added that while competition around the oxybate franchise remains a factor, it does not expect it to materially affect the company’s overall growth outlook.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) develops and commercializes pharmaceutical products across the United States, Europe, and international markets.